Advanced Or Metastatic Melanoma clinical trials

Explore recruiting advanced or metastatic melanoma clinical trials.

Recruiting advanced or metastatic melanoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Or Metastatic Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors

Spain, Poland, Italy, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

CRISPR-TIL for metastatic melanoma

Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

CRISPR-TIL for metastatic melanoma

Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

Netherlands, Belgium, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

ADP-TILIL7

Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Advanced Or Metastatic Melanoma trials by city

Advanced Or Metastatic Melanoma clinical trials

Recruiting advanced or metastatic melanoma studies right now

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

A Study of NX-1607 in Adults With Advanced Malignancies

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

AMT-253 in Patients With Advanced Solid Tumours

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Also recruiting in Europe

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors

CRISPR-TIL for metastatic melanoma

CRISPR-TIL for metastatic melanoma

An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

ADP-TILIL7

Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).

Advanced Or Metastatic Melanoma trials by city

Other conditions